Disclosed is an antibody that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the antibody comprises a heavy chain V-segment and a light chain V-segment, each of which comprises a complementarity determining region 1 (CDR1), a complementarity determining region 2 (CDR2), and a complementarity determining region 3 (CDR3) wherein: i) the CDR1 of the heavy chain V-segment comprises SEQ ID NO:7 ii) the CDR2 of the heavy chain V-segment comprises SEQ ID NO:10 iii) the heavy chain CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:12 and SEQ ID NO:13 iv) the CDR1 of the light chain V-segment comprises SEQ ID NO:21 v) the CDR2 of the light chain V-segment comprises SEQ ID NO:24 and vi) the light chain CDR3 comprises SEQ ID NO:26 wherein the sequences are as disclosed in the specification. Also disclosed is the use of the above mentioned antibody in the manufacture of a medicament for reducing LDL-C in an individual.
